Products for Research Use Only
RegisterLogin

CBT-295

CAT: 0931-T89861-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0931-T89861-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Target
Interleukin, TGF-beta/Smad
Related Pathways
Immunology/Inflammation, Stem Cells
Bioactivity
CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-β, TNF-α, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.
Molecular Formula
C18H20ClN3O
Molecular Weight
329.82
Shipping Conditions
Ice Packs
Storage Temperature
-20°C

Related Products

CatalogName
T208930-01ICG-CBT
TP3089-01QMT-CBT
T26512-01ABD-295
T25011-01AK-295
T202126-01PRL-295
TMPY-05083-01Tissue Factor Protein, Human, Recombinant (aa 1-295, His)
TMPK-01139-01TIM-1/KIM-1/HAVCR1 Protein, Human, Recombinant (aa 21-295, His)
TYD-01263-01CBTF sodium
T16393-01ONO-2952
T11719L-01JMV 2959

Alternative Products

CatalogName
GTR19238024-01CBT-295
HY-P10674QMT-CBT
HY-D2247ICG-CBT
111990Anti CBT (cannabicitran) cannabitriol Pab
TRC-T012750-100MGTCV 295
MBS5776244ABD-295
4322/2JH 295
M10252SMM-295
HY-171035-01PRL-295
HY-119378-01AK 295

Popular Products